Advertisement

Advertisement

ALLO Stock Latest News

Citizens biotech analyst holds an analyst/industry conference call

The FlyCitizens biotech analyst holds an analyst/industry conference call

Citizens biotech analysts hold an analyst/industry conference call

PremiumThe Fly

Citizens biotech analysts hold an analyst/industry conference call

9d ago

Allogene Launches ATM Offering to Bolster Capital Flexibility

PremiumCompany Announcements

Allogene Launches ATM Offering to Bolster Capital Flexibility

19d ago

Allogene Therapeutics Names Zachary Roberts as New CEO

PremiumCompany Announcements

Allogene Therapeutics Names Zachary Roberts as New CEO

1M ago

Allogene Therapeutics says Zachary Roberts to succeed David Chang as CEO

PremiumThe Fly

Allogene Therapeutics says Zachary Roberts to succeed David Chang as CEO

1M ago

Allogene Earnings Call Highlights Early CAR-T Momentum

PremiumCompany AnnouncementsAllogene Earnings Call Highlights Early CAR-T Momentum

2M ago

Allogene Therapeutics Balances Bold Data With Rising Spend

Company Announcements

Allogene Therapeutics Balances Bold Data With Rising Spend

2M ago

Allogene’s UNIVERSAL Trial Completion: What ALLO-715 Data Could Mean for Investors

Company Announcements

Allogene’s UNIVERSAL Trial Completion: What ALLO-715 Data Could Mean for Investors

2M ago

Allogene Therapeutics reports Q1 EPS (18c), consensus (18c)

PremiumThe Fly

Allogene Therapeutics reports Q1 EPS (18c), consensus (18c)

2M ago

Allogene Highlights ALPHA3 Data and Extended Cash Runway

PremiumCompany Announcements

Allogene Highlights ALPHA3 Data and Extended Cash Runway

2M ago

Allogene Therapeutics increases 2026 operating cash expense guidance

PremiumThe Fly

Allogene Therapeutics increases 2026 operating cash expense guidance

2M ago

Allogene Therapeutics options imply 10.6% move in share price post-earnings

PremiumThe Fly

Allogene Therapeutics options imply 10.6% move in share price post-earnings

2M ago

ALLO Upcoming Earnings Report: What to Expect?

PremiumPre-EarningsALLO Upcoming Earnings Report: What to Expect?

2M ago

Allogene Therapeutics expands Phase 2 ALPHA3 trial to South Korea, Australia

The Fly

Allogene Therapeutics expands Phase 2 ALPHA3 trial to South Korea, Australia

3M ago

Allogene Therapeutics price target lowered to $11 from $12 at H.C. Wainwright

The Fly

Allogene Therapeutics price target lowered to $11 from $12 at H.C. Wainwright

3M ago

Allogene Therapeutics upgraded to Neutral from Underweight at JPMorgan

PremiumThe Fly

Allogene Therapeutics upgraded to Neutral from Underweight at JPMorgan

3M ago

Allogene Therapeutics Prices Large Common Stock Offering

PremiumCompany Announcements

Allogene Therapeutics Prices Large Common Stock Offering

3M ago

Allogene Therapeutics price target raised to $10 from $6 at Jefferies

PremiumThe Fly

Allogene Therapeutics price target raised to $10 from $6 at Jefferies

3M ago

Unusually active option classes on open April 15th

PremiumThe Fly

Unusually active option classes on open April 15th

3M ago

Allogene Therapeutics 87.5M share Spot Secondary priced at $2.00

PremiumThe FlyAllogene Therapeutics 87.5M share Spot Secondary priced at $2.00

3M ago

Allogene Therapeutics price target raised to $3.85 from $1.60 at Bernstein

The Fly

Allogene Therapeutics price target raised to $3.85 from $1.60 at Bernstein

3M ago

Allogene Therapeutics price target raised to $9 from $7 at Baird

The Fly

Allogene Therapeutics price target raised to $9 from $7 at Baird

3M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >